Pre Market
|
||||
|
|
|
|
Regular Hours
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| Valuation Estimation |
|
EPS (Current/Estimated)
-0.23/-5.17
|
|
Enterprise Value
10.42M
|
| Balance Sheet |
|
Book Value Per Share
8.06
|
| Cash Flow |
|
Cash Flow Yield
0.01
|
| Income Statement |
|
Total Revenue
0
|
|
Operating Revenue Per Share
0.00
|
|
Industry Comparison
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quotes are at least 15-min delayed:2025/11/20 08:48 EST
Industry overview quotes are at least 15 minutes delayed
|
Business Description
|
|||
| Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorderswith high unmet medical need. |

4.41 

--